AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
Lilly posts Lyumjev safety results in India; registers new Alzheimer's Phase 1 studySep 29Weekly roundup, 5 itemsbaricitinibCipla
FDA approves efficacy supplement for Eli Lilly's Olumiant (baricitinib)Sep 25Regulatory decisionbaricitinibEli Lilly
Lilly posts orforglipron Phase 3 results; adds new early-phase studiesAug 14Weekly roundup, 6 itemsbaricitinibbrenipatide
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Lilly posts ACHIEVE-J results; Olumiant, Strattera labels updatedJul 2Weekly roundup, 5 itemsabemaciclibbaricitinib
Sign inSign in